CYBER-INTELLIGENCE-HOUSE
19.11.2021 09:02:09 CET | Business Wire | Press release
Hoxhunt, a premium enterprise cybersecurity awareness training platform, and Cyber Intelligence House, a leading provider of cyber intelligence, today announced a first-of-its-kind partnership designed to equip organizations with unprecedented protection from email attacks leveraging advanced insight across their dark-web-to employee-inbox lifecycle.
Hoxhunt’s CEO, Mika Aalto stated:
“This partnership with Cyber Intelligence House will open a whole new category of proactive cybersecurity awareness. Their industry-leading Cyber Exposure Platform adds a superior breadth and depth of intelligence from the Darkweb, Deep web and cyberspace forums and marketplaces to our dynamic awareness platform, typically 16 times more data than other solutions. By connecting threat intelligence with awareness, we can transform insight into foresight. Just imagine knowing an attack is likely coming and being able to train your employees with simulations of the actual phishing templates hackers purchased for their attack”.
Cyber Intelligence House’s CEO, Mikko Niemela adds:
“We are very excited to be partnering with Hoxhunt. Their best-in-class Cyber Awareness and Training platform allows organisations to adapt and defend against the ever rising volume of cyber threats that our platform identifies”.
About Hoxhunt:
Hoxhunt is a People-First Cybersecurity Platform that protects organizations and their employees from the risk of cyber attacks. Hoxhunt’s cognitive automation maps individually adaptive training curriculum to each employee’s skill level for optimal engagement. Hoxhunt empowers individuals with the tools and confidence to recognize and respond to attacks dynamically over time.
Hoxhunt enables security teams with real-time visibility into threats so they can react fast and limit their spread. The entire platform is autonomous, freeing up considerable time for security teams to focus on what matters.
To learn more about Hoxhunt, please visit https://www.hoxhunt.com or email info@hoxhunt.com .
About Cyber Intelligence House:
Cyber Intelligence House is a leading cyber intelligence company specialised in helping cyber security professionals and law enforcement to assess and monitor cyber exposure from the dark web, deep web, data breaches and online-assets. It is the trusted provider to government and law enforcement agencies globally, including Interpol and UNODC.
Cyber Intelligence House’s Cyber Exposure Platform (CEP) provides the world’s most comprehensive Cyber Threat database with over 10 years of data. 24/7 and collection and storing of new data at a rate of ~600 pages per second. CEP delivers unrivalled search and alerting performance with Deep scanning of over 250 metadata factors and machine learning enabled categorization of threats to provide deep insights into potential cyber threats.
To learn more about Cyber Intelligence House, please visit https://www.cyberintelligencehouse.com or email info@cyberintelligencehouse.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom